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Cytokines in clinical cancer immunotherapy
Pedro Berraondo1,2,3, Miguel F. Sanmamed1,2,3,4, María C Ochoa1,2,3, Iñaki Etxeberria1,2,3, Maria A. Aznar1,2,3, José Luis Pérez-Gracia1,2,3,4,
María E. Rodríguez-Ruiz1,2,3,4, Mariano Ponz-Sarvise1,2,3,4, Eduardo Castañón1,2,3,4 and Ignacio Melero1,2,3,4
Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities
of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and
interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. These early milestones in immunotherapy
have been followed by the recent addition to clinical practice of antibodies that inhibit immune checkpoints, as well as chimeric
antigen receptor T cells. A renewed interest in the anti-tumour properties of cytokines has led to an exponential increase in the
number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in
combination with other immunomodulatory drugs. These second-generation drugs under clinical development include known
molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to
the tumour microenvironment or to the desired effector immune cells. In addition, the detrimental activity of immunosuppressive
cytokines can be blocked by antagonistic antibodies, small molecules, cytokine traps or siRNAs. In this review, we provide an
overview of the novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials.
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INTRODUCTION
Cytokines are polypeptides or glycoproteins with a molecular
weight usually below 30 kDa that provide growth, differentiation
and inflammatory or anti-inflammatory signals to different cell
types. Cytokines are most often released during a defined period
in response to a stimulus, and the extent of their action is short-
lived due to their limited half-life in the circulation. As a result,
cytokines normally exert an autocrine or paracrine effect. As an
exception to the general rule, cytokines such as interleukin (IL)-7
or haematopoietic growth factors are produced homeostatically in
a continuous fashion.
Cytokine target cells express high-affinity receptors on their
cellular membrane. Following cytokine binding, the receptors
trigger intracellular signalling which leads to modifications in gene
transcription. Cytokines thereby modify proliferation and differ-
entiation and induce or modify particular cell functions. Target
cells expressing the corresponding sets of receptors integrate the
information derived from the concentration and timing of
exposure to different cytokines. Thus, synergy or antagonism
among different cytokines is a common characteristic, with high
degrees of complexity.
Cytokines as a monotherapy
Several cytokines limit tumour cell growth by a direct anti-
proliferative or pro-apoptotic activity, or indirectly by stimulating
the cytotoxic activity of immune cells against tumour cells. A
paradigmatic case is interferon-alpha (IFN-α), first discovered in
1957 as a result of its antiviral properties.1 After 13 years, Gresser
and Bourali2 described the anti-tumour activity of IFN-α against
different tumour cell lines inoculated in mice. This discovery of the
ability of cytokines to potentiate immune responses against
cancer in conjunction with the development of recombinant DNA
technologies led, in the 1980s and 1990s, to intense preclinical
and clinical investigation of the potential anti-tumour activity of
several recombinant cytokines. However, results from clinical trials
failed to meet the high expectations raised in preclinical models
and highlighted the limitations of approaches based on unmo-
dified recombinant proteins. These limitations include the short
half-life of most cytokines and narrow therapeutic windows with
only modest anti-tumour efficacy, at least as monotherapies. Only
two cytokines, IL-2 and IFN-α, demonstrated mild clinical
benefit and consequently received The Food and Drug Adminis-
tration (FDA) approval for the treatment of several malignant
diseases. IL-2 was approved for the treatment of advanced renal
cell carcinoma (RCC)3 and metastatic melanoma,4 whereas IFN-α
was approved for the treatment of hairy cell leukaemia,5 follicular
non-Hodgkin lymphoma,6 melanoma7 and AIDS-related
Kaposi’s sarcoma.8 The clinical use of these cytokines marked a
milestone in cancer immunotherapy, as it was the first
demonstration that immunotherapy could favourably tilt the
balance between cancer and the anti-tumour immune response,
leading to durable objective responses. However, the low
response rate and high toxicity associated with high-dose IL-2
and IFN-α administration have relegated the clinical use of these
cytokines in favour of targeted therapy and immune checkpoint
inhibitors.9,10
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Potentiating the effects of immunotherapies
Immune checkpoint inhibitors represent a revolution in cancer
immunotherapy. Clinical immunotherapy with monoclonal
antibodies to block the CTLA-4 (cytotoxic T-lymphocyte-
associated protein 4) or programmed cell death protein 1 (PD-
1)–PD-1 ligand (PD-L1) axes have been FDA-approved for the
treatment of several malignancies such as melanoma, non-small
cell lung cancer, RCC, Hodgkin lymphoma, Merkel cell carci-
noma, head and neck cancer and carcinoma of the bladder.
These novel therapies have yielded long-lasting responses in a
fraction of patients. In contrast to recombinant IL-2 or IFN-α as
mentioned above, immune checkpoint inhibitors have a more
favourable safety profile. Any adverse effects are mainly
autoimmune-like syndromes that can usually be controlled by
treatment with corticosteroids or other anti-inflammatory drugs,
such as infliximab.11 The synergistic combination of anti-CTLA-4
and anti-PD-1 monoclonal antibodies has been approved for the
treatment of advanced melanoma, microsatellite instability-high
or mismatch repair-deficient metastatic colorectal cancer and
advanced RCC by the FDA and has improved the overall
response rate of patients.12–14 The clinical success of this
combination provides the rationale for new combination
approaches in immunotherapy.15 In this context, cytokines are
being incorporated into combination clinical trials, mainly in
conjunction with anti-PD-1 and anti-PD-L1 monoclonal
antibodies.
Adoptive T cell therapies are also coming of age due to
impressive efficacy results and FDA approval of anti-CD19
chimeric antigen receptor (CAR) T cells,16 and the use of cultures
of tumour-infiltrating T lymphocytes (TILs).17 Notably, these
approaches are totally dependent on cytokines for in vitro
expansion and in vivo persistence of transferred T cells. These
cellular immunotherapies can be optimised by the incorporation
of cytokine genes into the lentiviral vector that encodes the
CARs.18
The search for the next generation of cytokine-based drugs is
based on three concepts. The first concept is synergistic
combinations, such that the approved anti-PD-1–PD-L1 mono-
clonal antibodies and CAR19 T cells provide a suitable basis for
combining with cytokines. The second concept looks at improved
pharmacokinetics. The systemic administration of cytokines
requires optimisation of the pharmacokinetic profile to increase
the half-life in circulation (surpassing the kidney filtration thresh-
old) and to increase the cytokine concentration in the tumour
microenvironment (TME). This aim can be achieved by conjugat-
ing polyethylene glycol (PEG) to the cytokine or by constructing a
fusion protein with antibodies, Fc domains, apolipoprotein A-I,
albumin or the latent peptide of transforming growth factor-β
(TGF-β). The third concept is that of local administration. An
alternative strategy to achieve high local concentrations of
cytokines in the TME is to directly inject the recombinant
protein19 or intratumoural gene therapy vectors that encode the
cytokine20,21 into the TME. Clinical trials are currently making use
of oncolytic viruses, plasmid electroporation and intratumoural
injection of lipid nanoparticles loaded with modified messenger
RNAs.
In this review, we describe how these blueprint concepts are
being applied to several cytokine-based compounds already
undergoing clinical trials. Among the immunostimulatory cyto-
kines that potentiate immune responses against cancer, we focus
our review on IFN-α, the IL-2 family, IL-12, granulocyte-
macrophage colony-stimulating factor (GM-CSF) and IL-10. In the
case of immunosuppressive cytokines, we describe strategies to
block the activity of tumour necrosis factor-alpha (TNF-α), TGF-β
and cytokines that nurture tumour-associated myeloid cells, such
as colony-stimulating factor-1 (CSF-1). Finally, we discuss the key
concepts that must be considered for future development of
cytokine-based immunotherapy.
POTENTIATING THE IMMUNE RESPONSE
Pro-inflammatory cytokines can contribute to cancer immunother-
apy, acting on every phase of the cancer immunity cycle.22,23 Thus,
cytokines can improve antigen priming, increase the number of
effector immune cells in the TME and enhance their cytolytic
activity. However, making drugs based on cytokines requires fine-
tuning of their pharmacological properties using biotechnological
strategies.
Interferon-α
Since the first approval of IFN-α for the treatment of hairy cell
leukaemia in 1986, this family of cytokines has been used for the
treatment of several haematological malignancies and solid
tumours at high doses to exploit their direct pro-apoptotic/anti-
proliferative activity on tumour cells. These high doses of IFN-α
also exert anti-tumour activity due to effects on the tumour
vasculature as IFN-α displays a potent antiangiogenic activity.24
PEGylated IFN-α was also approved for the adjuvant treatment of
melanoma.25 This variant consists of a chemical modification that
increases its half-life in circulation and therefore prolongs the
exposure of the tumour cells to high IFN-α concentrations.
However, the advent of targeted therapies and novel immu-
notherapies with superior safety and efficacy profiles has reduced
clinical use of IFN-α in oncohaematology. This situation might be
reverted with new cytokine modifications that exploit the
immunostimulatory properties of IFN-α, as this cytokine is critical
for the maturation of dendritic cells (DCs) and for the acquisition
of effector function by T lymphocytes.26
One strategy to unplug the cytotoxic activity of IFN-α from its
immunostimulatory activity involves its fusion to apolipoprotein
A-I.27 The apolipoprotein A-I moiety incorporates the cytokine into
high-density lipoproteins, improving the pharmacokinetics and
anti-tumour activity of IFN-α.28,29 AcTakines, activity-on-Target
cytokines, can also minimise the toxicity of IFN-α and maximise its
immunostimulatory activity. This strategy is based on the fusion of
a mutated cytokine that shows reduced affinity for its receptor to
a cell-specific targeting domain. IFN-α fused to single domain
antibodies targeting Clec9A, a molecule expressed on DCs
specialised in cross-priming, displays a potent anti-tumour
effect.30 Finally, IFN-α immunocytokines have been demonstrated
to exert an anti-tumour effect mediated by the activation of
immune system cells.31,32 In summary, type I IFN immunobiology
is likely to be exploited in the near future but is not currently in
the frontline oncology armamentarium.
Interleukin-2
IL-2 is viewed as a key cytokine in promoting the expansion of
natural killer (NK) cells and T lymphocytes. Thus, it is widely used
in protocols of adoptive transfer for both expanding lymphocytes
in culture and increasing the persistence of transferred cells in
cancer patients. The infusion of this cytokine at high doses is
currently approved for the treatment of metastatic RCC and
metastatic melanoma. However, the systemic administration of
this cytokine at the recommended dose is hampered by its toxic
profile, which includes frequent grade 3 and 4 adverse effects.
Second-generation IL-2-based therapies with improved pharma-
cokinetic and pharmacodynamic profiles are being developed.
Improvement of the pharmacokinetic profile is achieved through
covalent binding of IL-2 to moieties that increase the half-life in
circulation, such as the Fc domains of immunoglobulins or PEG
molecules, or by chimerisation with antibodies that target the
cytokine to the TME. Improvement of the pharmacodynamic
properties is attained by using biotechnology tricks to reduce
binding to the high-affinity IL-2 receptor while maintaining
binding to the medium-affinity IL-2 receptor to increase the
amount of cytokine that is available to stimulate NK and T cells.
The IL-2 receptor is composed of three different complexes
formed by three chains (Fig. 1). The low-affinity receptor is
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composed of the IL-2Rα chain alone but does not trigger an
intracellular signalling cascade. Thus, the two receptors that
induce signalling are the medium-affinity and the high-affinity
receptors. The medium-affinity receptor is composed of the IL-2Rβ
chain and the common γ chain; when the IL-2Rα chain is also
present in the receptor complex, IL-2 is bound with high affinity.
IL-2Rα is highly expressed on T regulatory (Treg) cells and
therefore the high-affinity IL-2 receptor skews IL-2 activity towards
the expansion of Treg cells, while limiting the bioavailability of the
cytokine to stimulate anti-tumour effector NK and T lymphocytes.9
Several of these second-generation IL-2-based compounds
engineered to avoid binding to IL-2Rα/CD25 have reached clinical
trials. NKTR-214 is composed of recombinant IL-2 together with
multiple molecules of PEG. Directed PEGylation generates an
inactive cytokine with a long half-life in circulation. The PEG
groups are progressively released, yielding IL-2 molecules with
double or single PEGylation that can interact with the medium-
affinity IL-2 receptor but not with the high-affinity IL-2 receptor.33
This modified cytokine is being evaluated in clinical trials in
combination with the immune checkpoint inhibitors atezolizumab
(NCT03138889), nivolumab (NCT02983045, NCT03282344 and
NCT03435640) and nivolumab plus ipilimumab (NCT02983045).
As reported at the American Society of Clinical Oncology (ASCO)
annual meeting in 2018, NKTR-214 has undergone dose-escalation
studies and has also been used in combination with nivolumab to
treat 214 patients, showing promising response rates in
immunotherapy-naive patients suffering from melanoma, RCC or
NSCLC. In terms of safety, the combination was tolerated, and
comparative randomised studies will be performed to confirm
benefit over nivolumab single-agent therapy.34
Another strategy to avoid signalling through the high-affinity
receptor uses an engineered mutated IL-2 variant that shows
reduced binding to IL-2Rα. This mutant is fused to antibodies to
target the cytokine to the TME. In the case of cergutuzumab
amunaleukin, the IL-2 variant is fused to an antibody that targets it
to the carcinoembryonic antigen.35 A phase I clinical trial is
evaluating this fusion protein in combination with atezolizumab
(NCT02350673). In the case of RO6874281, the mutated cytokine is
fused to an antibody that targets the fibroblast activation protein
which is expressed by cancer-associated fibroblasts. This fusion
protein is being combined in clinical trials with the epidermal
growth factor receptor inhibitors trastuzumab or cetuximab
(NCT02627274), with atezolizumab (NCT03386721 and
NCT03063762) as well as with bevacizumab, a monoclonal
antibody that targets vascular endothelial growth factor (VEGF)
(NCT03063762).
Interleukin-15
IL-15 is mainly produced by activated myeloid cells as a
membrane-bound heterodimer associated with IL-15Rα in such a
way that it is trans-presented to NK cells and T cells expressing IL-
2/IL-15Rβ and the common γ chain receptor.36,37 Importantly, IL-
15 is critically needed for the ontogeny of NK cells and CD8+
T cells38,39 and also induces the proliferation, cytotoxic action and
the release of other cytokines such as IFN-γ38,40 from these cells,
highlighting its role in potentiating the immune response.
Preclinical observations strongly support the potential anti-
tumour activity of IL-15 mediated by NK cells and T lympho-
cytes.41,42 Unlike IL-2, IL-15 does not stimulate Treg cells, a subset
that might reduce the anti-tumour activity of NK and T cells. This is
due to the fact that IL-15 does not bind to the IL-2Rα chain (also
known as CD25).43
First-in-human clinical trials using recombinant aglycosylated IL-
15 produced in Escherichia coli consisted of intravenous bolus
administration to patients with advanced melanoma or RCC.
Patients showed an expansion of NK and CD8+ T cells in
peripheral blood, but there were severe adverse events and
dose-limiting toxicities, including high fever, hypotension and
thrombocytopenia.44 This trial stopped due to dose-limiting
toxicity at 1.0 μg/kg per day. There were no clinical responses
by Response Evaluation Criteria In Solid Tumours (RECIST) v1.1
criteria, but 5 out of 18 patients with malignant melanoma or RCC
showed a reduction of between 10% and 30% in their marker
lesion. In another clinical trial reported recently, IL-15 was
subcutaneously administered to patients with melanoma, RCC,
non-small cell lung cancer (NSCLC) or squamous cell head and
neck carcinoma.45 The maximum tolerated dose of IL-15
administered subcutaneously was significantly higher than the
dose that was feasible by intravenous bolus injection, and reached
3.0 μg/kg per day. The number of circulating NK cells dramatically
increased with IL-15 administration in a dose-dependent fashion.
There were no objective clinical responses in this trial, but several
patients had disease stabilisation, including a patient with RCC
whose disease was stable for over 2 years.45
In vitro and in vivo preclinical studies indicate that IL-15 is more
bioactive when trans-presented adsorbed onto the IL-15Rα
receptor subunit.46–48 Recombinant IL-15 is quickly eliminated
from the blood due to its small molecular size (it has an in vivo
half-life of 2.5 h), and several approaches have therefore focused
on designing more stable protein constructs encompassing IL-15
and IL-15Rα that display a longer half-life and better biodistribu-
tion parameters. The different therapeutic forms of IL-15 and its
signalling receptor are described below and schematically
represented in Fig. 2.
The recombinant protein RLI encompasses the binding domain
of IL-15Rα (the so-called sushi domain) bound to IL-15 by a flexible
linker; this fusion protein displays superagonistic activity towards
the IL-15R–β/γ complex and exerts anti-tumour properties in
in vivo models.49 Some variations of the original structure have
been made to redirect IL-15 to the tumour, such as the addition of
anti-CD20 or anti-GD2 antibody domains.50,51 Our group has
constructed a recombinant protein termed Sushi-IL15-Apo, a triple
fusion protein comprising human IL-15, the binding domain of IL-
15Rα and apolipoprotein A-I. Apolipoprotein A-I, the major
component of high-density lipoproteins, binds to its main
receptor, SR-BI, which is overexpressed on liver and tumour cells,
thereby effectively targeting IL-15 activity within the recombinant
protein to the tumour.52–54
ALT-803, another variant of IL-15 that encompasses the sushi


















Fig. 1 Interleukin (IL)-2 receptors. IL-2 is recognised by three types
of receptor complex expressed on natural killer (NK) and T
lymphocytes. The non-signalling, low-affinity receptor is composed
of the IL-2Rα chain alone. The medium-affinity receptor is composed
of the IL-2Rβ chain and the common γ chain. Finally, the high-affinity
IL-2 receptor is composed of the IL-2Rα, the IL-2Rβ chain and the
common γ chain. Ligand binding to the medium-affinity and high-
affinity receptors leads to the phosphorylation of Janus kinase-1
(JAK1) and JAK3 and the recruitment and subsequent phosphoryla-
tion of signal transducer and activator of transcription-3 (STAT3) and
STAT5, and ensuing transcriptional changes
Cytokines in clinical cancer immunotherapy
P Berraondo et al.
8
shown to promote strong IL-15 activity in mouse models55 and
has been tested in clinical trials. In the dose-escalation phase I
clinical study with this recombinant protein, 33 patients with
haematological cancer received ALT-803 after disease relapse
following bone marrow allotransplantation.56 Sixteen subjects
received the treatment intravenously and 17 received it sub-
cutaneously. The treatment was well tolerated in both cohorts. All
patients showed an increase in the levels of circulating NK and
CD8+ T cells (the increase was more pronounced in the
subcutaneous treatment cohort), and 19% of the subjects met
criteria for clinical benefit. Another trial has been performed with
ALT-803 in 21 patients with metastatic NSCLC, testing escalating
doses via subcutaneous administration in combination with anti-
PD-1 therapy. The recombinant protein drug was well tolerated,
no dose-limiting toxicities were recorded and 29% of patients
achieved an objective response. A phase II continuation clinical
trial is ongoing (NCT02989844).57 It has also been reported that
ALT-803 is well tolerated in combination with intravesical bacillus
Calmette-Guérin therapy for high-risk localised bladder cancer,
achieving sustained complete responses for 24 months in 9 out of
9 patients.58 These data have led the FDA to grant fast-track
designation to this treatment for patients with non-muscle
invasive bladder cancer.
Other clinical studies involving IL-15 proteins as experimental
agents are ongoing. Most also include administering IL-15 in
combination with other agents. Some trials are testing IL-15 as an
adjuvant in T cell or NK cell adoptive cell therapies (NCT01875601,
NCT02465957 and NCT01385423). Other clinical studies
have been designed to test the ability of IL-15 to
increase antibody-dependent cellular cytotoxicity (ADCC) effects,
using IL-15 in combination with tumour-targeting monoclonal
antibodies such as alemtuzumab (NCT02689453) or rituximab
(NCT02384954).
Interleukin-21
IL-21 is another cytokine from the IL-2-family that is also being
actively tested in cancer clinical trials alone (NCT00095108,
NCT00514085 and NCT00336987) or in combination with ipilimu-
mab (NCT01489059), nivolumab (NCT01629758), sunitinib
(NCT00617253), rituximab (NCT00347971), sorafenib
(NCT00389285) or doxorubicin (NCT00523380). In a dose-
escalation phase I trial, there were pharmacodynamic effects of
anti-tumour immunity upregulation, and 3 out of 26 patients
experienced objective partial responses.59 In non-Hodgkin lym-
phoma patients, recombinant IL-21 has been tested in combina-
tion with rituximab, achieving clinical responses in 8 out of 19
patients.60 There is also interest in using IL-21 to potentiate
adoptive T cell therapy.61 However, the clinical development of
this cytokine is still in its infancy and progress is likely to occur in
the form of combinations.
Interleukin-10
IL-10 is released by innate and adaptive immune cells to fine-tune
the activity of pro-inflammatory cytokines.62 IL-10 is considered to
be an immunosuppressive cytokine as it can decrease the antigen-
presenting activity of DCs63 and inhibit the cytotoxic and cytokine-
release functions performed by T and NK lymphocytes.64 However,
recent reports point to a context-dependent outcome of IL-10
activity.65 In chronic infections and cancer, autocrine IL-10
activity on CD8+ T lymphocytes has been shown to be crucial
for inhibiting antigen-induced CD8+ T cell apoptosis,
thereby prolonging the effector activity of these cytotoxic
lymphocytes.66,67 This concept has been evaluated in a phase I
clinical trial in advanced, treatment-refractory tumours
(NCT02009449) using IL-10 conjugated with PEG to increase its
half-life. Administration of the PEGylated cytokine (termed
pegilodecakin) is well tolerated, and grade 3–4 immune-related
adverse effects were detected in only 15% of patients. Partial
responses were observed in patients with uveal melanoma, RCC
and colorectal cancer.68 At ASCO 2018, it was reported that the
combination of pegilodecakin with nivolumab or pembrolizumab
was tolerable in 38 patients with RCC. The clinical activity of
pegilodecakin looks promising, with 50% of patients achieving a
RECIST 1.1 response, 9% of which were complete.69
Interleukin-12
The IL-12 family comprises unique heterodimeric cytokines that
include IL-12, IL-23, IL-27 and IL-35. The heterodimeric 70 kDa
biologically active form of IL-12 (p35–p40) is composed of two
independently produced subunits, α (IL12p35) and β (IL12p40),
linked by disulphide bonds. The α subunit (IL12p35) shares
sequence homology with IL-6 and can also be part of IL-23
(p19–p40), whereas the β subunit (IL12p40) is shared with IL-35
(p35/Ebi3).70
IL-12 is mainly produced by activated antigen-presenting cells
such as DCs, macrophages, monocytes and B cells. IL-12
production is a tightly controlled process, regulated mainly at
the transcriptional level. Production is initiated by activation of
pathogen recognition receptors such as Toll-like receptors in
antigen-presenting cells upon sensing of pathogen-associated
molecular patterns) or damage-associated molecular patterns.71 In
addition, cytokine stimulation and direct immune cell–cell contact,
including CD40–CD40L interactions, induce IL-12 production. This
latter CD40-dependent mechanism is likely to be the principal
mechanism for the production of IL-12 in cancer.72 IL-12 binds to
the IL-12 receptor (IL-12R), expressed as a high-affinity hetero-
dimer of IL-12Rβ1 and IL-12Rβ2 subunits mostly on T cells and NK
cells. The β1 subunit is constitutively expressed on immune cells,
whereas the β2 subunit is upregulated in T cells and NK cells upon
activation.73
IL-12R activation results in the recruitment of the kinases Janus













Fig. 2 Engineered interleukin-15 (IL-15) variants. IL-15 is mainly
produced as a membrane-bound heterodimer associated with IL-
15Rα. The interaction of the IL-15–IL15-Rα complex with IL-2/IL-15Rβ
and the common γc receptor triggers the phosphorylation of Janus
kinase-1 (JAK1) and JAK3 and the recruitment and subsequent
phosphorylation of signal transducer and activator of transcription-3
(STAT3) and STAT5. Clinical trials have tested the safety and efficacy
of recombinant aglycosylated IL-15 and engineered variants to
mimic the trans-presentation process and to enhance the half-life in
circulation. These variants included the superagonist RLI protein
(comprising the binding domain of IL-15Rα fused to IL-15), ALT-803
(comprising mutated IL-15 fused to the binding domain of IL-15Rα
and an IgG1 Fc domain) and Sushi-IL15-Apo (a fusion protein
encompassing the binding domain of IL-15Rα, IL-15 and apolipo-
protein A-I)
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transducer and activator of transcription 4 (STAT4). Dimerisation
and nuclear translocation of phosphorylated STAT4 ultimately
leads to IFN-γ production, transcriptional reprogramming of CD4+
and CD8+ T cells towards type 1 T helper (Th1) cell differentiation
and maturation of NK cells. IFN-γ causes a FAS-ligand-dependent
collapse of the myeloid compartment and M1 macrophage
polarisation, paving the way for an optimal T cell infiltration and
cytolytic function.74,75 Furthermore, the potent antiangiogenic
properties of IL-12 also render it an attractive cytokine for cancer
treatment.71,76 The antiangiogenic effects are mediated by the
production of IFN-γ which alters extracellular matrix remodelling
and the expression of adhesion molecules on endothelial cells.77
An interesting antiangiogenic loop involving IL-12, IFN-γ and CXC
chemokine ligand 10 (CXCL10) has been discovered and involves
CXCR4 expression on proliferating vascular endothelial cells.78
In preclinical studies, systemic administration of recombinant IL-
12 induced potent anti-tumour efficacy in xenograft mouse
models.75,79 However, in clinical trials, the short half-life of the
recombinant protein in serum meant that high and multiple doses
were required, which resulted in dose-related toxicities, mainly
caused by elevated levels of circulating IFN-γ.80 To overcome the
toxicities, different approaches have been proposed, focusing on
local delivery of IL-12 to avoid toxic systemic exposure. Several
preclinical studies exploiting local gene transfer using viral
vectors,81 liposomes82 or in vivo electroporation of an IL-12-
encoding plasmid in accessible tumour lesions83 have demon-
strated strong anti-tumour activity with no apparent toxicity.
Focusing on targeted protein delivery, a fusion protein encom-
passing single-chain IL-12 coupled to an extracellular double-
stranded-DNA binding antibody (which thereby targets tumour
necrotic areas) showed enhanced anti-tumour activity in mouse
models.84
IL-12-based local treatment can be synergistically combined
with adoptive T cell transfer. In relation to this approach, the use
of transgenic tumour-specific T cells engineered to secrete IL-12 in
the TME in response to TCR-mediated antigen stimulation was
evaluated in mouse models, and showed very promising
efficacy.85 However, leakage during production of the inducible
IL-12 by the adoptively transferred TILs was reported in a
subsequent clinical trial, leading to unacceptable toxicity, with
one lethal case.86
Local IL-12 delivery and the use of immunostimulatory
monoclonal antibodies can generate synergistic results. In line
with this, combining the local delivery of IL-12 with the blockade
of PD-1–PD-L1 has been shown to eradicate large established
tumours in preclinical models.81 An in vivo electroporation
approach is currently undergoing clinical trials for local delivery
of IL-12 as a single agent (NCT01579318, NCT00323206,
NCT01502293 and NCT02345330)87 and in combination with
pembrolizumab (NTC02493361 and NTC03132675).
Granulocyte-macrophage colony-stimulating factor
GM-CSF (CSF-2) is a clinically available recombinant cytokine used
to promote myeloid reconstitution after bone marrow transplan-
tation or following induction chemotherapy in patients with acute
myelogenous leukaemia. This cytokine promotes the expansion
and activation of myeloid cells such as DCs and macrophages. For
this reason, it provides an adjuvant effect for various types of
vaccines. As a serious drawback, however, GM-CSF also promotes
the differentiation and accumulation of tumour-associated mye-
loid cells which support tumour growth. Subcutaneous recombi-
nant GM-CSF given in combination with ipilimumab improved the
overall survival and reduced ipilimumab-related toxicity in
patients with advanced melanoma.88 The adjuvant activity of
GM-CSF is exploited in the FDA-approved drug talimogene
laherparepvec (T-VEC). This genetically modified herpes simplex
virus encodes GM-CSF and, upon intratumoural injection, has
demonstrated overall response benefit over subcutaneous GM-
CSF in advanced melanoma patients.89 GM-CSF gene transfection
into autologous or allogeneic tumour cells has been the basis for
GVAX products which, in the allogeneic setting, have not met
satisfactory endpoints in prostate cancer phase III trials, but hold
promise in the autologous setting and in combination regimens in
pancreatic cancer.90,91
INHIBITING THE IMMUNOSUPPRESSIVE ACTIVITY
Cytokines might be released or activated in the TME by tumour
cells or infiltrating immune cells to promote all phases of
tumourigenesis. In this case, strategies to neutralise the patho-
genic activity of such cytokines can be developed to enhance
cancer immunotherapy. These strategies not only include the use
of antagonistic antibodies but also polypeptides, cytokine traps,
small interfering RNA (siRNA) and small molecules that inhibit
signal transduction from cytokine receptors. However, it must be
kept in mind that, like double-edged swords, some of these
cytokines may exert pro- and anti-tumour activities, depending on
context and elements in the TME.
TNF-α
TNF-α is a pro-inflammatory cytokine produced mainly by
myeloid-derived cells such as monocytes, macrophages and DCs,
although many other cells such as T lymphocytes, endothelial
cells, adipocytes and fibroblasts can also produce this cytokine
under stressful conditions. TNF-α is recognised by two receptors
with a broad tissue distribution: TNFR1 and TNFR2.92
TNF-α is a key pathogenic mediator of several autoimmune
diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative
colitis, psoriasis, psoriatic arthritis and ankylosing spondylitis. TNF-
α activates macrophages at the inflammation site inducing the
release of other pro-inflammatory cytokines that exacerbate
inflammation. The activity of TNF-α on epithelial cells impairs
barrier function and promotes permeability to commensal
bacteria. The activity of TNF-α on fibroblasts leads to the
expression of metalloproteinases and the synthesis of collagen,
thereby promoting tissue fibrosis. Finally, TNF-α acts on endothe-
lial cells to increase the adhesion molecules expressed on blood
vessels, subsequently leading to increases in leucocyte infiltration;
it might also induce endothelial cell apoptosis.
The relevance of this cytokine in autoimmune diseases led to
the generation and approval of several TNF-α antagonists such as
infliximab, adalimumab and etanercept.92 Infliximab is also
included in the guidelines for the treatment of several
autoimmune-like syndromes that are associated with immune
checkpoint inhibitor treatment that are refractory to corticosteroid
treatment.11
In cancer immunotherapy, TNF-α is mainly considered as a
mediator of anti-tumour immune responses, and several immu-
notherapies have shown depleted anti-tumour efficacy when co-
administered with TNF-α antagonists.93,94 It is likely that acute
immune responses are boosted by TNF-α release. However,
chronic exposure to TNF-α can promote tumour growth by
mediating activation-induced cell death of effector T lympho-
cytes.95 In mouse models, TNF-α has been shown to have a
detrimental effect on immunotherapies based on the blockade of
the PD-1 pathway. The proposed mechanism involves the TNF-α-
mediated upregulation of the secondary checkpoint component
TIM-3 in CD8+ T lymphocytes, induced by anti-PD-1 antibody
therapy.96 Safety of the triple combination of ipilimumab,
nivolumab and an antibody to block TNF-α (infliximab or
certolizumab) is being evaluated in a phase I clinical trial
(NCT03293784).
TGF-β
TGF-β plays a dual role in the tumourigenic process. During the
initial stages of tumourigenesis, TGF-β inhibits tumour
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development due to cell-cycle blockade in cells undergoing
transformation. However, tumour cells develop resistance
mechanisms to the anti-proliferative activity of TGF-β,97 and in
later stages of tumour development, TGF-β acts both on tumour
cells and on cells of the TME to promote tumour progression. In
tumour cells, TGF-β is a key mediator of the
epithelial–mesenchymal transition. In the tumour stromal com-
partments, this cytokine promotes the release of angiogenic
factors, such as VEGF, and the recruitment of Treg cells and
myeloid cells with a pro-tumour polarisation, such as neutrophils,
macrophages, myeloid-derived suppressor cells (MDSCs) and
tolerogenic DCs. Moreover, TGF-β decreases the activity of NK
cells and CD8+ T lymphocytes.98
The relevance of the immunosuppressive activity of this
cytokine in tumours has been conducive to the development of
several small molecules, peptides, antisense oligonucleotides,
cytokine traps and antibodies to block the TGF-β pathway in
cancer.98 Although their efficacy as monotherapy agents has been
disappointing, their activity in combination with anti-PD-1 or anti-
PD-L1 agents has renewed interest in inhibitors tackling the
functions of this cytokine. TGF-β might be the main driver of
immune cell exclusion in several tumours.99 Numerous clinical
trials are testing the safety and anti-tumour activity of the
combined blockade of TGF-β using small molecules, such as
galunisertib, or antagonistic monoclonal antibodies, such as
fresolimumab, with PD-1–PD-L1 such as nivolumab or durvalumab
(NCT02423343 and NCT02734160). Additionally, M7824, a com-
pound designed to simultaneously block both of these targets, is
undergoing clinical testing (NCT03451773 and NCT03451773). This
construct combines a chimeric version of an anti-PD-L1 mono-
clonal antibody (avelumab) with a fragment of TGF-βR4 to
entrap active TGF-β.100 Inhibiting this cytokine could be
especially relevant in tumours treated with radiotherapy, as
radiotherapy activates the latent form of TGF-β and induces its
transcription.101,102
CSF-1 and other cytokines that promote myeloid cells
Immune cells differentiated from haematopoietic myeloid pre-
cursors are key components of the immune response. The myeloid
cells that can be found in tumours are tolerogenic DCs, tumour-
associated macrophages (TAMs), tumour-associated neutrophils
and MDSCs, all of which comprise a heterogenous population of
immature myeloid precursors arrested in their differentiation
process.76,103
Tumour-released factors promote the expansion, recruitment
and polarisation of these myeloid cell populations, which
reciprocally support tumour development through the release of
anti-inflammatory cytokines, pro-angiogenic mediators and
growth factors. Furthermore, these cells express immune check-
point ligands such as PD-L1 on their surface, as well as enzymes
that promote metabolic alterations in the TME. All these
mechanisms reduce the release of cytokines by, and cytotoxic
activity of, NK and T lymphocytes. Strategies to counteract these
tumour-promoting activities involve depleting or repolarising
myeloid cells to restore efficient activity of anti-tumour effector
immune cells such as NK cells, Th1 CD4+ T lymphocytes and CD8+
cytotoxic T lymphocytes, as well as their infiltration into the
malignant tissue.76
CSF-1 receptor, the receptor for CSF-1 and IL-34, is expressed on
TAMs and maintains the homoeostasis of myeloid cells. By
contrast, M1 macrophages with anti-tumour activity are not
dependent on the CSF-1 receptor, making this pathway an
excellent target for small molecules, such as pexidartinib, or
monoclonal antibodies, such as cabiralizumab. CSF-1R
blockade leads to the alteration of macrophage polarisation in
the TME, which shows lower myeloid cell content associated with
a certain degree of tumour regression in preclinical animal
models.104,105
The accumulation of myeloid cells in the TME is orchestrated by
chemokine gradients. The most relevant cytokines in myeloid cell
recruitment are CXCL8 (also known as IL-8), CC chemokine ligand
2 (CCL2), CCL3 and CCL5.106 CXCL8/IL-8 is produced by tumour
cells, and elevations in the serum concentrations of this
chemokine reflect tumour growth dynamics and have been
proposed as a biomarker that can predict the response to anti-PD-
1 monoclonal antibodies in melanoma and NSCLC.107 An antibody
to block the interaction of CXCL8/IL-8 with its receptors on
myeloid cells, CXCR1 and CXCR2, has been tested in a phase I
clinical trial in patients with metastatic or unresectable, locally
advanced stage solid tumours (NCT02536469) and is now entering
into a phase Ia/II study in combination with nivolumab
(NCT03400332).108,109
CCR2 is the receptor for CCL2, while CCR5 binds both to CCL3
and CCL5. CCR2/CCR5 inhibitors are being developed to
synergistically block the activity of these chemokines, thereby
inhibiting myeloid cell recruitment, in combination with either
chemotherapy or nivolumab in patients with metastatic colorectal
cancer or pancreatic cancer (NCT03184870). Both CCR2 and CCR5
are involved in the recruitment of Treg cells, TAMs and MDSCs.
CCR2 is also involved in the bone marrow egress of myeloid cells.
In addition, CCR5 blockade can repolarise TAMs from a pro-
tumourigenic phenotype to an M1 phenotype.110
Finally, several small molecules and monoclonal antibodies
targeting the VEGF pathway have been approved for the
treatment of several types of cancer. These compounds were
originally developed to interfere with the angiogenic activity of
VEGF-A, but it is now known that this pleiotropic cytokine is also
involved in the recruitment of immunosuppressive myeloid cells
to the TME.111 The relevance of this concept in the clinic has been
highlighted by the results of the phase II study of atezolizumab
with or without bevacizumab in patients with untreated meta-
static RCC. Patients who showed tumour immune signatures of T
effector cells and myeloid cell infiltration were refractory to
treatment with atezolizumab alone but responded to the
combination of bevacizumab and atezolizumab.112 Moreover, a
combination of bevacizumab plus atezolizumab plus chemother-
apy provides evidence for activity against NSCLC as reported in
ASCO 2018.113 The combination of bevacizumab and atezolizu-
mab has also been tested in a phase I trial for advanced
hepatocellular carcinoma patients, showing good tolerability and
a very promising 62% overall response rate.114
CONCLUSIONS
Cytokines are potent but complex immune mediators. Making
cytokine-based drugs is a formidable challenge that requires a
profound knowledge of cytokine biology and contemporary
biotechnology to exploit their anti-tumour activity while keeping
toxicity to a minimum. The approved monoclonal antibodies
against the PD-1–PD-L1 axis provide a tool to reinvigorate effector
lymphocytes but primary and acquired resistance mechanisms
limit the fraction of patients who benefit from these novel
immunotherapies. Cytokines will be key molecules to overcome
such resistance mechanisms due to their ability to expand and
reactivate effector NK and T lymphocytes and promote tumour
infiltration by lymphocytes as well as their persistence in the TME.
Current excitement surrounding the immunobiology of cytokines
has resulted in a number of ongoing clinical trials (Table 1), the
results of which are eagerly expected. The possibility of blocking
cytokines and chemokines that mediate the recruitment of Treg
cells and tumour-associated myeloid cells might expose an as yet
under exploited Achilles’ heel in tumours, against which we can
deploy promising combination strategies.
In future developments, two key aspects are to be considered:
confining the effects of the cytokines to the site of action to avoid
systemic pro-inflammatory effects, and including these treatments
Cytokines in clinical cancer immunotherapy
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in combination immunotherapy strategies.15 For the first point,
approaches based on targeting agents to the TME or intratu-
moural administration of the proteins or their encoding genes can
be envisioned. These tumour-targeted approaches would also be
relevant for the neutralisation of immunosuppressive cytokines.
Cytokines in the realms of gene therapy, cell therapy and
monoclonal antibody-based therapies might become formidable
partners in elegant synergistic strategies (Fig. 3), whose anti-
tumour efficacy only the future will reveal.
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